(redirected from Inosine monophosphate)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.


 (I) [in´o-sēn]
a purine nucleoside containing the base hypoxanthine and the sugar ribose, which occurs in transfer RNAs.
inosine monophosphate (IMP) a nucleotide produced by removal of the amine group from adenosine monophosphate in metabolism of purine nucleotides.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

in·o·sine (I, Ino),

9-β-d-Ribosylhypoxanthine; a nucleoside formed by the deamination of adenosine.
Synonym(s): hypoxanthinosine
Farlex Partner Medical Dictionary © Farlex 2012


(ĭn′ə-sēn′, -sĭn, ī′nə-)
A nucleoside that is involved in purine metabolism, as a precursor and a metabolite of adenosine.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


(I, Ino) (in'ō-sēn)
A nucleoside formed by the deamination of adenosine.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

inosine (I)

a NUCLEOSIDE found in some ANTICODONS of TRANSFER RNA. Inosine is ribosylhypoxanthine, the base being hypoxanthine, a derivative of ADENINE. Inosine generally occurs in the first position of the anticodon of certain tRNA molecules where it can base pair with U, C or A of the CODON on mRNA.
Collins Dictionary of Biology, 3rd ed. © W. G. Hale, V. A. Saunders, J. P. Margham 2005
References in periodicals archive ?
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid.
This suggests that MPNs were preferentially methylated by thiopurine methyltransferase between 6 and 20 h, rather than converted by inosine monophosphate dehydrogenase and guanosine monophosphate synthetase into TGNs.
Because the M-2 metabolite is known to inhibit, in vitro, the inosine monophosphate dehydrogenase activity (5), the Emit assay would better reflect the entire MMF immunosuppressive property.
MMF is metabolized to mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (1MPDH), a key enzyme in the ex novo synthesis of GTP (1, 2).
Mycophenolic acid (MPA), (3) the active metabolite of the pro-drug mycophenolate mofetil (MMF), provides effective immunosuppression by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo pathway of DNA synthesis that is responsible for guanine production.
Its immunosuppressive activity is thought to reside in the inhibition of inosine monophosphate dehydrogenase (IMPDH), leading to a suppression of purine nucleotide synthesis in lymphocytes, thereby suppressing cell mitosis (3, 4).
MPA selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme that plays a pivotal role in synthesis of new DNA.
MPA mediates its effect by inhibiting inosine monophosphate dehydrogenase (1MPDH), an enzyme involved in the de novo biosynthesis of purine nucleotides [14,15].
Effect of human T lymphocyte activation on inosine monophosphate dehydrogenase expression.